These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14968138)

  • 1. Will regulation be the death of cell therapy in the United States?
    Gastineau DA
    Bone Marrow Transplant; 2004 Apr; 33(8):777-80. PubMed ID: 14968138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).
    Warkentin PI;
    Cytotherapy; 2003; 5(4):299-305. PubMed ID: 12944235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of cellular therapies: the Australian perspective.
    Wall DM; Prince HM
    Cytotherapy; 2003; 5(4):284-8. PubMed ID: 12944233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laying the regulatory path for advanced therapies.
    Nat Rev Drug Discov; 2008 Jun; 7(6):464-5. PubMed ID: 18511922
    [No Abstract]   [Full Text] [Related]  

  • 6. The long journey from stem cells to medical product.
    Parson A
    Cell; 2006 Apr; 125(1):9-11. PubMed ID: 16615881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process and product development in the manufacturing of molecular therapeutics.
    Atkinson EM; Christensen JR
    Curr Opin Mol Ther; 1999 Aug; 1(4):422-9. PubMed ID: 11713755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role and activities of the ISCT Regulatory Affairs Committee.
    Kelley L
    Cytotherapy; 2003; 5(4):279-83. PubMed ID: 12944232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical issues in tissue banking.
    Haimowitz MD
    Am J Clin Pathol; 1997 Apr; 107(4 Suppl 1):S75-81. PubMed ID: 9124234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding external controls over the commercial introduction of engineered human tissues. Assessing regulatory and liability issues.
    Smith DS
    Clin Plast Surg; 1999 Oct; 26(4):537-48, vii. PubMed ID: 10553211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient safety or profit: what incentives are blood shield laws and FDA regulations creating for the tissue banking industry?
    Williams JL
    Indiana Health Law Rev; 2005; 2(1):295-328. PubMed ID: 17111505
    [No Abstract]   [Full Text] [Related]  

  • 14. Cross-referencing of ISO-9000 and regulatory quality systems at blood centers.
    Healy-Collier K
    Top Health Inf Manage; 1998 May; 18(4):32-8. PubMed ID: 10179274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's proposed regulatory approach to regulation of hematopoietic stem/progenitor cell products.
    Harvath L
    Cytotherapy; 1999; 1(4):358-9. PubMed ID: 20440912
    [No Abstract]   [Full Text] [Related]  

  • 16. The challenges of regulating stem cell-based products.
    von Tigerstrom BJ
    Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
    Närhi M; Nordström K
    Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality control system to support comparability assessment for the Renal Bio-Replacement therapy system.
    Pitkin Z
    Dev Biol (Basel); 2005; 122():131-8. PubMed ID: 16375257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.